Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature Review

26 Jan 2024

Abstract excerpt

Anaplastic lymphoma kinase (ALK) rearrangement is a well-known driver oncogene detected in approximately 5% of non-small cell lung cancer. However, ALK rearrangement is much less frequent in other solid tumors outside the lungs, such as colorectal cancer (CRC); thus, the optimal management of CRC with ALK rearrangements has yet to be established. In this report, we describe 2 cases of ALK-positive CRC, both of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Gastric Cancer Management and Outcomes
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38381603
DOI: 10.1093/oncolo/oyae020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature ReviewPMID 38381603Read ↗

Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the LiteratureSemantic proximity Read ↗

Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.Semantic proximity Read ↗

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.Semantic proximity Read ↗

Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer.Semantic proximity Read ↗

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerSemantic proximity Read ↗

Targeting Anaplastic Lymphoma Kinase in Lung CancerSemantic proximity Read ↗

Oncogenic <i>ALK</i> Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic TargetSemantic proximity Read ↗

Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.Semantic proximity Read ↗

ALK gene amplification is associated with poor prognosis in colorectal carcinomaSemantic proximity Read ↗

MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases.Semantic proximity Read ↗

Crizotinib: an anaplastic lymphoma kinase inhibitor.Semantic proximity Read ↗

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.